Georgia CTSA COVID-19 Response


Georgia CTSA is taking an active role in monitoring the COVID-19 pandemic and sharing important news updates. We are continuously collecting and sharing news of how our trainees, scholars, investigators, faculty, and staff are responding to the COVID-19 virus. Learn more about what we are doing and resources available to you.

Featured News

Georgia CTSA Leader Discusses Importance of COVID-19 Trials on NPR Affiliate

Lilly Immergluck, MD, MSM Associate Professor and Pediatric Clinical & Translational Research Unit Director, and Georgia CTSA Pediatrics Co-Director and Integrating Special Populations Co-Investigator, discussed combating the global pandemic and COVID-19 trials on WABE radio, an NPR affiliate. Immergluck remarked that communities of color are being disproportionately affected by the virus. She and her team are working with a Community Advisory Board for involvement in study design, participant feedback, and information sharing. Immergluck also emphasized to listeners the importance of wearing a mask and getting a flu shot.

Outstanding Results from Phase 3 COVID-19 Vaccine Trial Led by Former Georgia CTSA KL2 Scholar

On November 15, 2020, less than one year after a novel coronavirus was reported by Chinese health authorities, the NIH-appointed Data Safety Monitoring Board reported that the mRNA-1273 vaccine candidate used in this Phase 3 COVID-19 trial was safe and well-tolerated with a vaccine efficacy rate of 94.5%. This Phase 3 trial is a nationwide trial in 100 sites with 30,000 participants across the U.S. designed to evaluate the investigational vaccine that was co-developed by the National Institute of Allergy and Infectious Diseases (NIAID) and the biotechnology company Moderna, Inc.

Georgia CTSA Leader Heads NIH’s Georgia CEAL to Address COVID-19 Disparities

For outreach and engagement efforts in ethnic and racial minority communities disproportionately affected by the pandemic, the National Institutes of Health has created the Community Engagement Alliance (CEAL) Against COVID-19 Disparities initiative. NIH selected teams in 11 states to focus on counties with underserved communities to facilitate the inclusion and participation in COVID-19 vaccine and therapeutic clinical trials.

Community Engagement Alliance (CEAL) Against COVID-19 Disparities

Download resources for use in talking to your communities about COVID-19, the vaccines under development, how they are developed, and the importance of being included in research studies. Review information on educating and recruiting clinical trial participants and ensuring diversity in clinical trials. Use the link above to bookmark these resources and return often for new resources to help you engage community organizations and individuals.

NIH Delivering New COVID-19 Tests Validated by Georgia CTSA Leaders

The National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx) initiative has awarded contracts to seven biomedical diagnostic companies whose innovative technologies will increase the availability of COVID-19 tests by millions per week as early as September 2020. While expanding the nation’s testing capacity, these testing technologies use different methods including more convenient sampling, such as saliva testing, while some technologies provide results within minutes at the point of care including schools, offices, and nursing homes. Two of Georgia CTSA’s leaders head up the NIBIB-funded Atlanta Center Microsystems Engineered Point of Care Technologies (ACME POCT) which was selected by the NIH, along with their institutions - Emory, Georgia Tech, and Children’s Healthcare of Atlanta - to test and validate some of the most promising technologies for COVID-19 diagnostic tests.

Georgia CTSA Leads Serosurvey for CDC and FEMA COVID-19 Responders

Georgia CTSA and Emory University including the Emory Medical Laboratory assisted the Centers for Disease Control and Prevention (CDC) and the Federal Emergency Management Agency (FEMA) in conducting a serosurvey to assess the presence of antibodies to SARS-CoV-2 among their workforce who are participating in the COVID-19 response. Georgia CTSA completed more than 1,200 blood draws for a COVID-19 serology (antibody) testing for CDC first responders and Emory Healthcare staff for the COPE study. Additionally, Georgia CTSA helped test 476 blood samples from FEMA and HHS first-line responders stationed in Washington, DC for a total of just under 1,700 tests.

Georgia CTSA Investigators Encouraged by COVID-19 Vaccine Trial

Georgia CTSA investigators Evan Anderson, MD, and Nadine Rouphael, MD, co-authored results published in NEJM reporting a robust anti–SARS-CoV-2 immune response in all study participants during the investigational mRNA-1273 vaccine phase 1 trial. Anderson is the principal investigator and Rouphael is the contact principal investigator for the trial at Emory. 

NIH Launches National COVID Cohort Collaborative (N3C)

The NIH has launched a centralized, secure enclave to store and study vast amounts of medical record data from people diagnosed with coronavirus disease across the country. It is part of an effort, called the National COVID Cohort Collaborative (N3C), to help scientists analyze these data to understand the disease and develop treatments. This effort aims to transform clinical information into knowledge urgently needed to study COVID-19.

Georgia CTSA Leaders to Begin Phase 1 Validation for National COVID-19 Tests

Two of Georgia CTSA's leaders head up the NIBIB-funded Atlanta Center Microsystems Engineered Point of Care Technologies (ACME POCT) which has been selected by the NIH, along with their institutions - Emory, Georgia Tech, and Children’s Healthcare of Atlanta - to test and validate some of the most promising technologies for COVID-19 diagnostic testing for NIH’s Rapid Acceleration of Diagnostics (RADx) Initiative.

Former Georgia CTSA KL2 Scholar Helps Lead COVID-19 Research Efforts

As an accomplished research physician-scientist with several NIH R01 grants as Principal Investigator, Colleen Kelley MD, MPH, Associate Professor, Emory University School of Medicine, Division of Infectious Diseases, and Georgia Clinical & Translational Science Alliance (Georgia CTSA) former KL2 Scholar is actively involved in several research efforts around COVID-19 including ongoing clinical trials and related research activities.

Georgia CTSA CPTR Graduate's Anti-Inflammatory Drug Selected for International Phase 3 COVID-19 Trial

Christina Gavegnano, PhD, Assistant Professor, Emory University School of Medicine, and Georgia Clinical & Translational Science Alliance (Georgia CTSA) Certificate Program in Translational Research (CPTR) graduate, has been working with Baricitinib for the indication of HIV and shares the internationally-issued patent for use for viral infections. Baricitinib has been selected by the National Institutes of Health (NIH) for a multi-country phase 3 study for COVID-19 treatment.

COVID-19 Prevention Measures Advocated by Georgia CTSA MSCR Grad

Marybeth Sexton, MD, MSc, Assistant Professor, Emory University School of Medicine, member of the Serious Communicable Disease Unit team at Emory University Hospital and Georgia Clinical & Translational Science Alliance (Georgia CTSA) Master in Science in Clinical Research (MSCR) graduate, has been actively sharing COVID-19 prevention and protective strategies to limit the spread of COVID-19. Her current focus is on communicating the importance of social distancing during the pandemic.

Georgia CTSA MSCR Grad Helps Develop Best Practices for COVID ICU

Sara Auld, MD, MSc, Assistant Professor, Emory University School of Medicine and Rollins School of Public Health, and Georgia Clinical & Translational Science Alliance (Georgia CTSA) Master in Science in Clinical Research (MSCR) graduate, has helped her team develop best practices and guidelines for ICU patients at Emory University Hospital Midtown who have COVID-19.

Georgia CTSA Former Trainee Scales Up In-House COVID-19 Test

Paulina Rebolledo, MD, MSc, Assistant Professor, Emory University School of Medicine, Division of Infectious Diseases, Rollins School of Public Health, Hubert Department of Global Health and Georgia Clinical & Translational Science Alliance (Georgia CTSA) Master in Science in Clinical Research (MSCR) graduate, has worked with her team to scale up an in-house COVID-19 diagnostic test at Grady Memorial Hospital.

Former Georgia CTSA Trainee Helps Lead ICU Response to COVID-19

Annette Esper, MD, MSc, Associate Professor, Emory University School of Medicine, Division of Pulmonary and Critical Care Medicine, and Georgia Clinical & Translational Science Alliance (Georgia CTSA) Master in Science in Clinical Research (MSCR) graduate, is engaged with her team in Grady’s ICU in the ongoing battle against COVID-19. The team restructured their current intensive care units and deployment of those units. Since there are multiple ICUs at Grady, the team cohorted the COVID patients and designated a specific ICU a COVID ICU.

Georgia CTSA MSCR Graduates on Front Line of COVID-19 Battle

Jeffrey Collins, MD, MSc, Assistant Professor, and Russell Kempker, MD, MSc, Associate Professor, Emory University School of Medicine, Division of Infectious Diseases, NIH-funded physician-scientists, and Georgia Clinical & Translational Science Alliance (Georgia CTSA) Master in Science in Clinical Research (MSCR) graduates, are on the front lines of the battle against COVID-19. Collins and Kempker were both on Infectious Diseases clinical service at Grady Hospital when the SARS-CoV2 virus came to Atlanta and diagnosed the first patients seen at Grady with COVID-19.

Georgia CTSA Rapid Response Team Coordinates 48-Hour Approval for Treatment of Coronavirus Patient

Emory's first coronavirus patient began receiving infusion therapy as a result of Georgia CTSA's assistance in coordinating the approvals needed within 48 hours. Georgia CTSA's Navigator Team utilized the new Standard Operating Procedure (SOP) for its Rapid Response Team service to obtain fast-track approvals across the Emory system.

Georgia CTSA Leader Named to Georgia's Coronavirus Task Force

Georgia CTSA Clinical Research Centers (GCRCs) Director Colleen Kraft, MD, MSc, has been named to Georgia Governor Brian Kemp's Coronavirus Task Force. The 18-member task force of health, airport, school and emergency preparedness officials has been asked to identify the best way to prevent the spread of the coronavirus in Georgia.

Funding Opportunities

NIH Funding Opportunities Specific to COVID-19

This page contains a listing of active funding opportunities specific to COVID-19.

COVID-19 Resources and Guidance: Information You Need, When and Where You Need It

View up-to-date NIH COVID-19 information including Informational Videos; Proposal Submission & Award Management Resources; Human Subjects & Clinical Trials Guidance; Animal Welfare; Frequently Asked Questions regarding flexibilities for grantees and Funding Opportunities.

WHSC COVID-19 Center for Urgent Research Engagement (COVID-19 CURE) and Awards Program – Rolling Acceptance until December 15

The Woodruff Health Sciences Center (WHSC) announces the launch of the WHSC COVID-19 CENTER for URGENT RESEARCH ENGAGEMENT (COVID-19 CURE) and Awards Program, made possible by generous philanthropic support from the O. Wayne Rollins Foundation and the William Randolph Hearst Foundation. The CURE Center was created to facilitate high-impact science and discovery towards improved COVID-19 treatment and prevention research. The funds can be used to support new COVID-19 focused researchers, equipment/instrumentation, technical support, pilots and enhancing facilities for this work. In addition, COVID-19 CURE will act as a hub, facilitating and helping to prioritize Emory COVID-19 research activities. 

Research Resources

N3C COVID-19 Analytics Platform Now Open

Researchers studying COVID-19 now are able to access an innovative new analytics platform that contains clinical data from the electronic health records of people who were tested for the novel coronavirus or who have had related symptoms. Part of the NCATS National COVID Cohort Collaborative (N3C) Data Enclave, the centralized and secure data platform features powerful analytics capabilities for online discovery, visualization and collaboration.

COVID-19 Collaboration Platform

The COVID-19 Collaboration Platform brings unassociated research teams working on the same clinical research questions together to share protocols, data, and evidence. COVID-19 Collaboration Platform offers support managing collaborations, including expedited and prioritized help from the Trial Innovation Network and SMART IRB to form multi-site trials; expert statistical advice for aggregated analyses, and free data storage and anonymization through vivli.org.

Community Resources

Participants Needed for COVID-19 Vaccine and Therapeutic Trials

Adults 18 and older, from all races and ethnicities, are needed to participate in COVID-19 trials. Please spread the word to help recruit minorities, especially for vaccine trials. Register Register online or contact Hope Clinic (Decatur), 404-712-1371; Emory Children’s Center (main campus), 404-727-4044; or Ponce CRS (Downtown/Grady), 770-286-3327.

Special Webinar Events

Upcoming

Blue Sky Group: COVID–19 and Cardiovascular Complications
January 13 | 4:00 PM - 5:30 PM 

View Previous Events and Webinar Sessions:

Blue Sky Groups

Special COVID Webinars